CA
GNMX

Cliff Asness’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Cliff Asness’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-18,927
Closed -$114K – 2322
2015
Q4 		$114K Buy
+18,927
New +$129K ﹤0.01% 2206

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Cliff Asness's GNMX Position: Q1 2016 in Review

Cliff Asness sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2016, closing a stake of 18,927 shares — an estimated $114K sold.

Cliff Asness first reported a position in GNMX in Q4 2015 and held it in 1 quarter. The position peaked at $114K in Q4 2015. 56 funds tracked by Wall St. Rank hold GNMX as of Q1 2016.

  • Cliff Asness reported no remaining Aevi Genomic Medicine Inc position as of Q1 2016 after selling out during the quarter.
  • Cliff Asness sold 18,927 Aevi Genomic Medicine Inc shares in Q1 2016, an estimated $114K.
  • Cliff Asness first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 1 quarter.
  • Cliff Asness's Aevi Genomic Medicine Inc position peaked at $114K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2016.

Based on AQR Capital Management's 13F filing for Q1 2016, filed 16 May 2016.